Own stocks of companies that get drugs approved. That hasn’t been so easy. But the U.S. Food & Drug Administration (FDA) has ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...

As a potential strike of Canada Post workers looms, the Crown corporation says it its “operating as normal” while negotiations with the union continue. If a strike does go ahead, at least one ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to the onset of a vaso-occlusive crisis (VOC) as ...

Nicolle Pangis, a former CEO of the cable-ad-sales entity Ampersand, will join Netflix as its new vice president of advertising, a role that has not been easy to navigate at the streaming giant as ...